Saudi Chemical inks deal to buy prescription rights for Cialis in Saudi Arabia

28/12/2021 Argaam

Logo of Saudi Chemical Company Holding

Saudi Chemical Company Holding and Eli Lilly signed, on Dec. 27, an acquisition agreement, whereby the former will acquire all prescription rights of Cialis (5mg and 20mg) in Saudi Arabia.

 

The company said in a bourse filing that the completion of the transaction is conditional on the approval of relevant government bodies.

 

Cialis is used to treat men with erectile dysfunction and the signs and symptoms of benign prostatic hyperplasia (enlarged prostate gland that is not cancerous).

 

Through this acquisition, AJA Pharmaceutical Industries (AJA Pharma), a subsidiary of Saudi Chemical, will become the manufacturer and supplier for Cialis in the Kingdom.

 

Cialis’ annual revenues in Saudi Arabia are expected to reach around SAR 100 million ($26.7 million).

 

For More M&As

Comments {{getCommentCount()}}

Be the first to comment

{{comment.FollowersCount}}
{{comment.CommenterComments}}

رد{{comment.DisplayName}} على {{getCommenterName(comment.ParentThreadID)}}

{{comment.DisplayName}} حساب موثّق

{{comment.ElapsedTime}}
{{comment.Replies.length}}
تعديل
loader Train
Report
loader Train
Sorry: the validity period has ended to comment on this news
Opinions expressed in the comments section do not reflect the views of Argaam. Abusive comments of any kind will be removed. Political or religious commentary will not be tolerated.